Literature DB >> 2522806

HLA-DR expression by high grade superficial bladder cancer treated with BCG.

S Prescott1, K James, A Busuttil, T B Hargreave, G D Chisholm, J F Smyth.   

Abstract

The local immune response to intravesical BCG therapy for widespread carcinoma in situ and superficial bladder tumour was assessed using immunohistochemical methods on serial biopsies obtained during treatment. The main findings were the induction of a strong level of HLA-DR expression by urothelial cells which persisted for several months after completion of therapy. This coincided with a mononuclear cell infiltrate in the bladder wall consisting predominantly of activated helper T lymphocytes. Smaller numbers of macrophages, suppressor cytotoxic T lymphocytes and B lymphocytes were also found. These new findings confirm that the inflammatory response to BCG involves the urothelium in an immunological reaction and suggest that the success of immunotherapy with intravesical BCG may be due to enhanced tumour antigen recognition.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522806     DOI: 10.1111/j.1464-410x.1989.tb05187.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  24 in total

Review 1.  Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.

Authors:  Elisa Tinazzi; Vincenzo Ficarra; Sara Simeoni; Walter Artibani; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2005-10-12       Impact factor: 2.631

2.  A tribute to professor Geoffrey D Chisholm CBE ChM PPRCS Ed FRCS Eng FRCP Ed FRCPSG FRACS (Hon) FCSSA (Hon) FACS (Hon) FRSE.

Authors:  G Williams
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

3.  Postoperative cytology in relation to recurrences of superficial bladder tumours.

Authors:  M Hanus; M Matouskova; H Smolova
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

4.  Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha.

Authors:  J L Haley; D G Young; A Alexandroff; K James; A M Jackson
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

5.  Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.

Authors:  L T Balemans; P D Vegt; P A Steerenberg; E C De Boer; A Van Swaaij; R E De Vries; A P Van der Meijden; W Den Otter
Journal:  Urol Res       Date:  1994

6.  Abnormal urothelial HLA-DR expression in interstitial cystitis.

Authors:  T J Christmas; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 7.  Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Authors:  J J Patard; D K Chopin; L Boccon-Gibod
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

8.  The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy.

Authors:  A M Jackson; S Prescott; S J Hawkyard; K James; G Chisholm
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

Authors:  M J Stassar; P D Vegt; P A Steerenberg; A P van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; W den Otter
Journal:  Urol Res       Date:  1994

10.  Denovo urothelial carcinoma of the upper and lower urinary tract in kidney--transplant patients with end-stage analgesic nephropathy.

Authors:  W F Thon; V Kliem; M C Truss; P Anton; M Kuczyk; C G Stief; R Brunkhorst
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.